⌕
Phathom Pharmaceuticals · PHAT · Nasdaq
Tenet 33 · Weak
Compare
$5.30−3.64%At closeTenet 33 · Weak
$5.30−0.20 (−3.64%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

Phathom Pharmaceuticals (PHAT) Stock

Phathom Pharmaceuticals (PHAT) closed at $5.30 on Nov 18, 2026; its Tenet Score is 33 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

35 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$5.30
Nov 18, 2026
Market cap
$447.1M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
5.01 – 18.31
low → high · as of close, Nov 17, 2026
Tenet Score
33/100
Weak · 340 Healthcare peers

Industry: Drugs

Phathom Pharmaceuticals Inc scores 33/100. Weak. Financial health is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 33 is built from 2 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data, and Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=340
33/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
34
Health
33
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value & Growth omitted — no data yet.
Value—QualityDHealthDGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
1.6×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 17, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−91.4%
fiscal 2025, before interest and tax
Net margin
−30.2%
TTM through Sep 30, 2026
Current ratio
1.76
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-com…

Composite computed Nov 17, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 44 US ETFs · top wrappers by weightSee all ETFs holding PHAT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 17, 2026.

What sector and industry is Phathom Pharmaceuticals in?

Phathom Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Phathom Pharmaceuticals' Tenet Score?

Phathom Pharmaceuticals' Tenet Score is 33 out of 100, ranked against 340 Healthcare peers as of Nov 17, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.